Takemura, K.; Ikeda, K.; Miyake, H.; Sogame, Y.; Yasuda, H.; Okada, N.; Iwata, K.; Sakagami, J.; Yamaguchi, K.; Itoh, Y.;
et al. Epithelial–Mesenchymal Transition Suppression by ML210 Enhances Gemcitabine Anti-Tumor Effects on PDAC Cells. Biomolecules 2025, 15, 70.
https://doi.org/10.3390/biom15010070
AMA Style
Takemura K, Ikeda K, Miyake H, Sogame Y, Yasuda H, Okada N, Iwata K, Sakagami J, Yamaguchi K, Itoh Y,
et al. Epithelial–Mesenchymal Transition Suppression by ML210 Enhances Gemcitabine Anti-Tumor Effects on PDAC Cells. Biomolecules. 2025; 15(1):70.
https://doi.org/10.3390/biom15010070
Chicago/Turabian Style
Takemura, Keisuke, Kyohei Ikeda, Hayato Miyake, Yoshio Sogame, Hiroaki Yasuda, Nobuhiro Okada, Kazumi Iwata, Junichi Sakagami, Kanji Yamaguchi, Yoshito Itoh,
and et al. 2025. "Epithelial–Mesenchymal Transition Suppression by ML210 Enhances Gemcitabine Anti-Tumor Effects on PDAC Cells" Biomolecules 15, no. 1: 70.
https://doi.org/10.3390/biom15010070
APA Style
Takemura, K., Ikeda, K., Miyake, H., Sogame, Y., Yasuda, H., Okada, N., Iwata, K., Sakagami, J., Yamaguchi, K., Itoh, Y., & Umemura, A.
(2025). Epithelial–Mesenchymal Transition Suppression by ML210 Enhances Gemcitabine Anti-Tumor Effects on PDAC Cells. Biomolecules, 15(1), 70.
https://doi.org/10.3390/biom15010070